CF33-CD19
AXP000101.1 · Oncolytic virus
- Platform
- chimeric orthopoxvirus (CF33)
- Originator
- City of Hope (Yuman Fong)
- Sponsor
- Imugene
Names
Virus
- Role
- Oncolytic
- Family
- Poxviridae
- Virus
- chimeric orthopoxvirus (CF33)
- Strain
- CF33
- Replication
- conditionally replicating
- Modifications
- engineered to express truncated human CD19 on infected tumour cells
- Transgenes
- CD19 (truncated)
- Route
- intratumoral, intravenous
- Source
- evidence
Cross-references
- NCI Thesaurus
- C201773
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06063317 | A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS) | Terminated | Phase 1 | 2023-10-02 | 2026-02-02 | 25 | Solid Tumor, Adult |
Recent changes
No changes recorded in its trials yet.
Clinical papers
No confirmed clinical papers yet.
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 38214445 | Using Oncolytic Virus to Retask CD19-Chimeric Antigen Receptor T Cells for Treatment of Pancreatic Cancer: Toward a Universal Chimeric Antigen Receptor T-Cell Strategy for Solid Tumor. | Journal of the American College of Surgeons | 2024 | name in abstract: CF33-CD19t |
Notes
Trade-named onCARlytics: paints tumour cells with truncated CD19 so that anti-CD19 agents (blinatumomab, CAR-T) can act. First patient dosed in the phase 1 OASIS trial in October 2023.
How to cite
CF33-CD19 (AXP000101.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000101.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.